|Bid||14.08 x 4000|
|Ask||14.09 x 3000|
|Day's range||14.01 - 14.12|
|52-week range||13.19 - 17.15|
|Beta (5Y monthly)||0.64|
|PE ratio (TTM)||34.32|
|Forward dividend & yield||0.66 (4.23%)|
|Ex-dividend date||29 Sept 2022|
|1y target est||N/A|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The U.S. Food and Drug Administration on Thursday approved Takeda Pharmaceutical's therapy to treat a rare genetic blood disorder in adult and pediatric patients. Takeda's Adzynma becomes the first treatment available to patients with congenital thrombotic thrombocytopenic purpura (TTP). Congenital TTP is a life-threatening, rare genetic disorder with debilitating chronic symptoms.
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q2 2023 Earnings Call Transcript October 27, 2023 Christopher O’Reilly: Thank you very much for joining us out of your busy schedule today for the earnings call for Second Quarter Fiscal 2023 with Takeda Pharmaceutical Company Limited. I am going to be the moderator today O’Reilly, the Head of IR. […]